Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, K Hideghety, P Klimak… - Investigational new …, 2014 - Springer
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee, K Hideghety… - 2014 - christie.openrepository.com
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in
combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic …
combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee… - Investigational …, 2014 - pubmed.ncbi.nlm.nih.gov
Aim To determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee… - INVESTIGATIONAL …, 2014 - biblio.ugent.be
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee… - Investigational New …, 2014 - search.proquest.com
The purpose of this paper is to determine whether EMD 1201081, a TLR9 agonist, added to
cetuximab had antitumor activity in second-line recurrent/metastatic squamous cell …
cetuximab had antitumor activity in second-line recurrent/metastatic squamous cell …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee… - INVESTIGATIONAL …, 2014 - lib.ugent.be
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee… - Investigational new …, 2014 - europepmc.org
Aim To determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
[引用][C] Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve …
A RUZSA, M SEN, J ERFAN… - Investigational new …, 2014 - pascal-francis.inist.fr
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in
combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic …
combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic …
Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee, K Hideghety… - Investigational New …, 2014 - infona.pl
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
[PDF][PDF] Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve …
A Ruzsa, M Sen, M Evans, LW Lee, K Hideghety… - 2014 - academia.edu
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …